Trial Profile
A randomized, double-blind, placebo- and active-controlled, cross over, single escalating dose study to assess the safety, tolerability and pharmacokinetics of compound G44 in healthy subjects
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs G 44 (Primary) ; Gabapentin
- Indications Partial epilepsies; Postherpetic neuralgia
- Focus Adverse reactions
- Sponsors Sun Pharma Advanced Research Company
- 20 Oct 2016 Status changed from not yet recruiting to discontinued.
- 18 Apr 2012 New trial record